Aldeyra Therapeutics Inc
NASDAQ:ALDX
Balance Sheet
Balance Sheet Decomposition
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
Balance Sheet
Aldeyra Therapeutics Inc
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
1
|
3
|
9
|
15
|
12
|
20
|
47
|
45
|
78
|
230
|
145
|
143
|
55
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
15
|
24
|
100
|
135
|
129
|
24
|
|
| Cash Equivalents |
0
|
1
|
3
|
9
|
15
|
12
|
20
|
45
|
29
|
54
|
129
|
9
|
14
|
31
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
13
|
13
|
23
|
46
|
29
|
0
|
0
|
30
|
0
|
47
|
|
| Total Receivables |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
2
|
5
|
3
|
7
|
5
|
3
|
|
| Total Current Assets |
0
|
2
|
3
|
9
|
28
|
25
|
44
|
95
|
75
|
83
|
233
|
181
|
148
|
104
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
2
+567%
|
4
+85%
|
9
+138%
|
28
+220%
|
25
-11%
|
44
+75%
|
95
+115%
|
76
-21%
|
83
+10%
|
233
+179%
|
181
-22%
|
148
-18%
|
105
-29%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
3
|
1
|
0
|
1
|
0
|
1
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
5
|
12
|
8
|
11
|
14
|
6
|
12
|
|
| Short-Term Debt |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
1
|
15
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Total Current Liabilities |
3
|
0
|
1
|
1
|
2
|
2
|
3
|
9
|
13
|
12
|
12
|
15
|
22
|
19
|
|
| Long-Term Debt |
0
|
27
|
5
|
1
|
1
|
1
|
1
|
0
|
15
|
11
|
16
|
15
|
0
|
15
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
|
| Total Liabilities |
3
N/A
|
27
+942%
|
6
-79%
|
3
-55%
|
3
+32%
|
4
+6%
|
5
+31%
|
9
+85%
|
27
+222%
|
24
-13%
|
27
+15%
|
30
+11%
|
29
-6%
|
34
+18%
|
|
| Equity | |||||||||||||||
| Common Stock |
13
|
29
|
38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
16
|
54
|
41
|
47
|
59
|
77
|
100
|
139
|
199
|
237
|
295
|
357
|
394
|
450
|
|
| Additional Paid In Capital |
0
|
0
|
1
|
53
|
84
|
99
|
139
|
225
|
247
|
296
|
500
|
508
|
514
|
521
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
2
N/A
|
25
-996%
|
2
+92%
|
6
N/A
|
25
+295%
|
22
-13%
|
40
+83%
|
87
+119%
|
48
-44%
|
60
+24%
|
206
+246%
|
151
-27%
|
120
-21%
|
71
-41%
|
|
| Total Liabilities & Equity |
0
N/A
|
2
+567%
|
4
+85%
|
9
+138%
|
28
+220%
|
25
-11%
|
44
+75%
|
95
+115%
|
76
-21%
|
83
+10%
|
233
+179%
|
181
-22%
|
148
-18%
|
105
-29%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
6
|
6
|
6
|
6
|
10
|
13
|
19
|
26
|
29
|
39
|
58
|
59
|
59
|
60
|
|